[Skip to Content]
[Skip to Content Landing]
Views 3,407
Citations 0
Clinical Trials Update
September 26, 2017

Injectable Buprenorphine Halts Effects of Opioids and May Deter Abuse

JAMA. 2017;318(12):1099. doi:10.1001/jama.2017.14120

A novel sustained-release formulation of buprenorphine (CAM2038) blocked the euphoric effects of illicit opioids and suppressed withdrawal in patients with opioid use disorder (OUD), according to a study published in JAMA Psychiatry. Weekly subcutaneous buprenorphine injections may prevent the misuse, diversion, and nonadherence associated with the current daily sublingual buprenorphine formulation, wrote the researchers.

×